Northeast Financial Consultants
LRMR icon

Northeast Financial Consultants’s Larimar Therapeutics LRMR Stock Holding History

Northeast Financial Consultants’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,105
Closed -$109K – 397
2021
Q4 		$109K Hold
10,105
– – 0.01% 347
2021
Q3 		$117K Buy
+10,105
New +$121K 0.01% 345
2020
Q2 		– Sell
-1,937
Closed -$18K – 301
2020
Q1 		$18K Hold
1,937
– – ﹤0.01% 270
2019
Q4 		$26K Hold
1,937
– – ﹤0.01% 304
2019
Q3 		$17K Hold
1,937
– – ﹤0.01% 322
2019
Q2 		$28K Buy
+1,937
New +$51.6K ﹤0.01% 326

Other funds holding LRMR

Deerfield Management
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

Northeast Financial Consultants's LRMR Position: Q1 2022 in Review

Northeast Financial Consultants sold out of Larimar Therapeutics (LRMR) in Q1 2022, closing a stake of 10,105 shares — an estimated $109K sold.

Northeast Financial Consultants first reported a position in LRMR in Q2 2019 and held it in 6 quarters. The position peaked at $117K in Q3 2021. 45 funds tracked by Wall St. Rank hold LRMR as of Q1 2022.

  • Northeast Financial Consultants reported no remaining Larimar Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Northeast Financial Consultants sold 10,105 Larimar Therapeutics shares in Q1 2022, an estimated $109K.
  • Northeast Financial Consultants first reported a position in Larimar Therapeutics in Q2 2019 and held it in 6 quarters.
  • Northeast Financial Consultants's Larimar Therapeutics position peaked at $117K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2022.

Based on Northeast Financial Consultants's 13F filing for Q1 2022, filed 12 May 2022.